Guardian Pharmacy Affirms FY26 Revenue View of $1.40B-$1.42B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Guardian Pharmacy affirms FY26 revenue view of $1.40B-$1.42B, consensus $1.42B
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRDN
Wall Street analysts forecast GRDN stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 38.590
Low
34.00
Averages
34.50
High
35.00
Current: 38.590
Low
34.00
Averages
34.50
High
35.00
About GRDN
Guardian Pharmacy Services, Inc. is a pharmacy services company. The Company provides a range of technology-enabled services designed to help residents of long-term care facilities (LTCFs) adhere to drug regimen. It offers compliance packaging service for repackaging and dispensing prescription and non-prescription pharmaceuticals in accordance with physician orders and delivers the medications to LTCFs for administration to individual residents. It organizes each resident’s medications into individual unit dose or multi-unit dose packaging in accordance with specific drug distribution rounds that occur at LTCFs at specific times throughout the day. Its pharmacy workflow software helps to manage and track drug dispensing via a structured and scalable workflow process, including the use of barcode technology. It offers Guardian Compass, which includes dashboards created to help local pharmacies plan, track and optimize business operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Guardian Pharmacy Q1 Earnings Beat Expectations
- Strong Earnings Performance: Guardian Pharmacy Services reported a Q1 non-GAAP EPS of $0.29, beating expectations by $0.05, which reflects the company's robust profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $336.6 million, exceeding forecasts by $6.71 million, indicating its competitive strength and sustained customer demand, further solidifying its market position.
- Net Income and Adjusted EBITDA: Q1 net income stood at $13.5 million with adjusted EBITDA at $29.8 million, demonstrating positive progress in cost control and operational efficiency, which supports sustainable growth moving forward.
- Optimistic Outlook: The company raised its annual adjusted EBITDA forecast midpoint to $125 million from $122 million while maintaining its revenue outlook midpoint at $1.41 billion, reflecting management's confidence in future performance and recognition of market potential.
See More
Guardian Pharmacy Services Reports Q1 2026 Earnings Amid IRA Challenges
- Revenue Growth: Guardian Pharmacy Services reported Q1 2026 revenue of $336.6 million, reflecting a 2% year-over-year increase despite a significant 60% decline in pricing for branded drugs under the IRA framework, demonstrating resilience in challenging conditions.
- Adjusted EBITDA Guidance Increase: Management raised full-year adjusted EBITDA guidance to $123 million to $127 million, incorporating a $3 million benefit recognized in Q1, indicating strong profitability amid new policy challenges.
- Increase in Resident and Script Volumes: The company reported a 10% year-over-year increase in total residents to approximately 207,000 and a similar 10% rise in script volumes, highlighting robust market demand and effective expansion of its customer base.
- Capital Markets Activity: The company executed an offering of 6.9 million Class A shares priced at $31 each during the quarter, although it currently has no plans to utilize the newly filed shelf registration, reflecting a cautious approach to capital management.
See More
Major Wall Street Rating Updates on Monday
- Cohu Rating Reiteration: Jefferies reiterates its Buy rating on Cohu with a price target of $55, viewing the company as an emerging enabler of higher-complexity semiconductor testing, which could enhance its market position significantly.
- Rollins Upgrade: Rothschild & Co Redburn upgrades Rollins from Neutral to Buy, raising the price target from $51.90 to $66, indicating a 16% upside, as they see the current share price as an attractive entry point for investors.
- Nutrien Upgrade: Barclays upgrades Nutrien from Equal Weight to Overweight, increasing the price target from $80 to $85, anticipating continued strength in the nitrogen segment due to the Iran conflict, which positions the company favorably in the market.
- Galaxy Digital Initiation: Chardan initiates coverage of Galaxy Digital with a Buy rating, highlighting its attractive position in the digital asset ecosystem and potential for integration with traditional financial markets, which could drive future growth.
See More
Guardian Pharmacy Services to Attend 2026 Healthcare Conference
- Conference Participation: Guardian Pharmacy Services will attend the Bank of America 2026 Healthcare Conference in Las Vegas on May 13, 2026, where CEO Fred Burke will participate in a fireside chat at 9:20 a.m. PDT, showcasing the company's leadership in long-term care pharmacy services.
- Investor Engagement: The event will feature a live audio webcast accessible through Guardian Pharmacy Services' website, allowing investors, analysts, media, and the public to engage, thereby enhancing transparency and interaction with stakeholders.
- Business Model: Guardian partners with long-term care facilities to deliver medications and technology-enabled services aimed at improving medication adherence, which helps reduce care costs and enhance clinical outcomes, highlighting its competitive edge in the industry.
- Network Expansion: As of December 31, 2025, Guardian operates 61 pharmacies, with 54 being full-service, serving nearly 205,000 residents, demonstrating its ongoing growth and influence in the long-term care market.
See More
Guardian Pharmacy Services to Release Q1 2026 Financial Results
- Earnings Release Announcement: Guardian Pharmacy Services has announced that it will release its Q1 2026 financial results after market close on May 6, 2026, with management hosting a conference call at 4:30 p.m. Eastern Time, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The conference call will be available via audio webcast, with investors able to participate through a designated link or by dialing a dedicated number for U.S. and Canadian participants, while international participants can access the call through provided international numbers, ensuring broad investor engagement and information dissemination.
- Company Overview: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, highlighting its significant position in the industry.
- Network Expansion: As of December 31, 2025, Guardian operates 61 pharmacies, 54 of which are full-service, serving approximately 205,000 residents, indicating the company's ongoing growth in the long-term care market and its commitment to customer service.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
Guardian Pharmacy Q1 Earnings Beat Expectations
- Strong Earnings Performance: Guardian Pharmacy Services reported a Q1 non-GAAP EPS of $0.29, beating expectations by $0.05, which reflects the company's robust profitability and boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $336.6 million, exceeding forecasts by $6.71 million, indicating its competitive strength and sustained customer demand, further solidifying its market position.
- Net Income and Adjusted EBITDA: Q1 net income stood at $13.5 million with adjusted EBITDA at $29.8 million, demonstrating positive progress in cost control and operational efficiency, which supports sustainable growth moving forward.
- Optimistic Outlook: The company raised its annual adjusted EBITDA forecast midpoint to $125 million from $122 million while maintaining its revenue outlook midpoint at $1.41 billion, reflecting management's confidence in future performance and recognition of market potential.
See More
Guardian Pharmacy Services Reports Q1 2026 Earnings Amid IRA Challenges
- Revenue Growth: Guardian Pharmacy Services reported Q1 2026 revenue of $336.6 million, reflecting a 2% year-over-year increase despite a significant 60% decline in pricing for branded drugs under the IRA framework, demonstrating resilience in challenging conditions.
- Adjusted EBITDA Guidance Increase: Management raised full-year adjusted EBITDA guidance to $123 million to $127 million, incorporating a $3 million benefit recognized in Q1, indicating strong profitability amid new policy challenges.
- Increase in Resident and Script Volumes: The company reported a 10% year-over-year increase in total residents to approximately 207,000 and a similar 10% rise in script volumes, highlighting robust market demand and effective expansion of its customer base.
- Capital Markets Activity: The company executed an offering of 6.9 million Class A shares priced at $31 each during the quarter, although it currently has no plans to utilize the newly filed shelf registration, reflecting a cautious approach to capital management.
See More
Major Wall Street Rating Updates on Monday
- Cohu Rating Reiteration: Jefferies reiterates its Buy rating on Cohu with a price target of $55, viewing the company as an emerging enabler of higher-complexity semiconductor testing, which could enhance its market position significantly.
- Rollins Upgrade: Rothschild & Co Redburn upgrades Rollins from Neutral to Buy, raising the price target from $51.90 to $66, indicating a 16% upside, as they see the current share price as an attractive entry point for investors.
- Nutrien Upgrade: Barclays upgrades Nutrien from Equal Weight to Overweight, increasing the price target from $80 to $85, anticipating continued strength in the nitrogen segment due to the Iran conflict, which positions the company favorably in the market.
- Galaxy Digital Initiation: Chardan initiates coverage of Galaxy Digital with a Buy rating, highlighting its attractive position in the digital asset ecosystem and potential for integration with traditional financial markets, which could drive future growth.
See More
Guardian Pharmacy Services to Attend 2026 Healthcare Conference
- Conference Participation: Guardian Pharmacy Services will attend the Bank of America 2026 Healthcare Conference in Las Vegas on May 13, 2026, where CEO Fred Burke will participate in a fireside chat at 9:20 a.m. PDT, showcasing the company's leadership in long-term care pharmacy services.
- Investor Engagement: The event will feature a live audio webcast accessible through Guardian Pharmacy Services' website, allowing investors, analysts, media, and the public to engage, thereby enhancing transparency and interaction with stakeholders.
- Business Model: Guardian partners with long-term care facilities to deliver medications and technology-enabled services aimed at improving medication adherence, which helps reduce care costs and enhance clinical outcomes, highlighting its competitive edge in the industry.
- Network Expansion: As of December 31, 2025, Guardian operates 61 pharmacies, with 54 being full-service, serving nearly 205,000 residents, demonstrating its ongoing growth and influence in the long-term care market.
See More
Guardian Pharmacy Services to Release Q1 2026 Financial Results
- Earnings Release Announcement: Guardian Pharmacy Services has announced that it will release its Q1 2026 financial results after market close on May 6, 2026, with management hosting a conference call at 4:30 p.m. Eastern Time, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The conference call will be available via audio webcast, with investors able to participate through a designated link or by dialing a dedicated number for U.S. and Canadian participants, while international participants can access the call through provided international numbers, ensuring broad investor engagement and information dissemination.
- Company Overview: Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy service providers, dedicated to partnering with long-term care facilities to deliver medications and technology-enabled services aimed at reducing care costs and improving clinical outcomes, highlighting its significant position in the industry.
- Network Expansion: As of December 31, 2025, Guardian operates 61 pharmacies, 54 of which are full-service, serving approximately 205,000 residents, indicating the company's ongoing growth in the long-term care market and its commitment to customer service.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
